Vilin Bio Med Limited (VILINBIO)
📢 Recent Corporate Announcements
Vilin Bio Med Limited announced the voting results and Scrutinizer's Report for its 20th Annual General Meeting (AGM) held on September 2, 2026. A total of 85,39,244 votes were polled across 1,52,50,000 outstanding equity shares, representing a 55.99% voter turnout. All 9 resolutions, including the adoption of FY26 financial statements, reappointment of retiring director Prasanna Lakshmi Venna, and approval of material related-party transactions with wholly owned subsidiary Axia Pharma Private Limited, were passed with 100% votes in favor.
- All 9 resolutions passed with 100% affirmative votes and zero votes cast against
- Total voter turnout was 55.99%, representing 85,39,244 votes out of 1,52,50,000 total shares
- Promoter group polled 80,59,819 votes (93.30% of their 86,38,574 shareholding)
- Public non-institutional shareholders cast 4,79,425 votes (7.25% of their 66,11,426 shareholding)
- Approved material related-party transactions to be entered into with wholly owned subsidiary Axia Pharma Private Limited
Vilin Bio Med Limited submitted the Scrutinizer's report and voting results for its 20th Annual General Meeting (AGM) held on September 2, 2026. All 9 resolutions presented in the AGM notice were passed with 100% majority, representing 8,539,244 valid votes cast and zero votes against. Approved items included the adoption of FY26 audited standalone financial statements and approvals for material related-party transactions with wholly-owned subsidiaries Vilo Speciality Pharma Private Limited and Axia Pharma Private Limited.
- All 9 resolutions passed with 100% affirmative votes (8,539,244 votes in favor, 0 against)
- Remote e-voting conducted from August 30, 2026 to September 1, 2026 based on the August 26, 2026 cut-off date
- Shareholders approved material related-party transactions with wholly-owned subsidiaries Vilo Speciality Pharma and Axia Pharma
- Adopted audited standalone financial statements for the financial year ended March 31, 2026
Vilin Bio Med Limited held its 20th Annual General Meeting (AGM) on September 2, 2026, via video conferencing with 9 members in attendance. Key resolutions tabled for shareholder approval included enabling resolutions to borrow in excess of paid-up capital and free reserves (Section 180(1)(c)), creating charges on company assets, and approving material related-party transactions with wholly owned subsidiaries Vilo Speciality Pharma and Axia Pharma. The scrutinizer's report on remote e-voting and meeting voting will be declared separately.
- Twentieth AGM conducted via video conference on September 2, 2026 (3:00 PM to 3:15 PM IST).
- 9 members attended the virtual AGM.
- Special resolutions proposed for borrowing powers beyond paid-up capital and creating charges on company assets.
- Shareholder approvals sought for material related-party transactions with wholly owned subsidiaries Vilo Speciality Pharma and Axia Pharma.
Vilin Bio Med Limited has received an observation letter with 'No Objection' from the National Stock Exchange (NSE) dated August 10, 2026, regarding its proposed merger with Chemgenix Laboratories Private Limited. This follows the initial merger announcement made on February 16, 2026. The scheme now moves toward the next stages of approval, including shareholders, creditors, and statutory authorities (NCLT). Given Vilin Bio's small market cap of ₹66 Cr and TTM revenue of ₹57 Cr, this amalgamation could be a significant event for the company's scale.
- Received NSE 'No Objection' observation letter on August 10, 2026.
- Amalgamation involves Chemgenix Laboratories Private Limited (Transferor) into Vilin Bio Med Limited (Transferee).
- The merger process was initiated approximately 6 months ago on February 16, 2026.
- Company currently operates with a lean TTM revenue of ₹57 Cr and a market cap of ₹66 Cr.
Vilin Bio Med Limited has announced the appointment of M/s Pawan Jain & Associates as Secretarial Auditors for a five-year term (FY 2026-27 to FY 2030-31) following the resignation of the previous auditor. The company has scheduled its 20th Annual General Meeting (AGM) for September 2, 2026, to be held via video conferencing. A cut-off date of August 26, 2026, has been established to determine shareholder voting eligibility. These administrative updates come as the company maintains a market capitalization of Rs 66 Cr and reported TTM revenue of Rs 57 Cr.
- Appointment of M/s Pawan Jain & Associates as Secretarial Auditors for a 5-year term until FY 2030-31
- 20th Annual General Meeting (AGM) scheduled for September 2, 2026, at 3:00 P.M. IST
- Cut-off date for e-voting eligibility fixed as August 26, 2026
- Remote e-voting period set from August 30, 2026 (9:00 A.M.) to September 1, 2026 (5:00 P.M.)
- Resignation of previous Secretarial Auditor, Mr. Kashinath Sahu, effective August 10, 2026
Vilin Bio Med (Market Cap: ₹60 Cr) has officially registered as a 'Manufacturer Exporter' with the Pharmaceuticals Export Promotion Council of India (Pharmexcil). This registration is a critical regulatory step enabling the company to export its pharmaceutical products and access international B2B markets. Given the company's current TTM revenue of ₹57 Cr and thin net margins, this move is intended to leverage its Roorkee manufacturing unit for higher-value international trade. While no specific orders were announced, this provides the legal and institutional framework for global market entry.
- Registered as 'Manufacturer Exporter' with Pharmexcil as of August 1, 2026
- Aims to leverage the existing Roorkee manufacturing unit for international market expansion
- Targeting growth beyond the current TTM revenue of ₹57 Cr
- Strategic move to improve global visibility and brand recognition for its unbranded portfolio
- Registration facilitates access to export incentives and overseas B2B healthcare stakeholders
Vilin Bio Med Limited (Market Cap: ₹60 Cr) has signed a Memorandum of Understanding (MOU) with Ideal Pharma BV, Netherlands, to collaborate on the distribution of generic and branded medicines across Europe. The partnership intends to leverage Ideal Pharma's established European wholesale distribution infrastructure. This represents a significant geographic expansion attempt for a company with a TTM revenue of ₹57 Cr. However, the MOU is non-binding regarding specific volumes, and definitive agreements are yet to be executed to finalize responsibilities.
- MOU signed on July 29, 2026, with Netherlands-based Ideal Pharma BV for European market entry.
- Collaboration covers both Generic and Branded Medicines using existing wholesale infrastructure.
- Vilin Bio Med currently operates with a thin 7.0% OPM and TTM revenue of ₹57 Cr.
- The agreement involves no equity issuance, special management rights, or changes in capital structure.
- Definitive agreements are required to govern specific future transactions or projects.
Financial Performance
Revenue Growth by Segment
The company operates in a single segment: manufacturing of pharmaceutical products. Revenue from operations for H1 FY26 (half-year ended September 30, 2025) grew by 115.08% YoY to INR 966.40 Lakhs compared to INR 449.32 Lakhs in H1 FY25. However, annual revenue for FY25 (INR 1,480.99 Lakhs) showed a decline of 6.29% compared to FY24 (INR 1,580.49 Lakhs).
Geographic Revenue Split
Not disclosed in available documents; however, the company maintains a manufacturing unit in Roorkee, Haridwar, and a registered office in Hyderabad, suggesting a primary focus on the Indian domestic market.
Profitability Margins
Profitability is thin due to high material costs. Net Profit Before Tax (NPBT) margin for FY25 was 2.06% (INR 30.58 Lakhs on INR 1,480.99 Lakhs revenue). For H1 FY26, the NPBT margin remained stable at 2.00% (INR 19.38 Lakhs on INR 966.40 Lakhs revenue).
EBITDA Margin
Core profitability is constrained by high raw material consumption. In FY25, the cost of materials consumed (INR 1,347.23 Lakhs) accounted for 90.97% of total revenue, leaving limited room for EBITDA expansion. Finance costs for FY25 were INR 84.51 Lakhs, which significantly impacted net margins.
Capital Expenditure
The company invested INR 157.47 Lakhs in the purchase of fixed assets during FY25. For the half-year ended September 30, 2025, additional capital expenditure of INR 28.69 Lakhs was recorded to support manufacturing capacity.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company incurred finance costs of INR 84.51 Lakhs in FY25 and INR 6.77 Lakhs in H1 FY26, indicating active debt servicing.
Operational Drivers
Raw Materials
Specific chemical or API names are not disclosed; however, 'Cost of Materials Consumed' is the primary driver, representing 90.97% of revenue in FY25 (INR 1,347.23 Lakhs) and 92.79% in H1 FY26 (INR 896.73 Lakhs).
Capacity Expansion
The company is expanding strategically by increasing manufacturing capacities at its Roorkee unit to enhance organizational output and tap into new market opportunities. Specific MTPA or unit capacity is not disclosed.
Raw Material Costs
Raw material costs are the most significant operational expense, totaling INR 1,347.23 Lakhs in FY25. The company's strategy involves alliances with business associates to boost selective product deals and manage procurement.
Manufacturing Efficiency
The company focuses on quality fulfillment to ensure customer satisfaction. Efficiency is monitored through internal financial controls which were audited and found adequate as of March 31, 2025.
Strategic Growth
Growth Strategy
Growth is targeted through strategic expansion of manufacturing capacities, enhancing organizational capabilities, and exploring untapped markets. The company plans to form alliances with business associates in the Indian market to boost its selective product portfolio.
Products & Services
The company manufactures unbranded pharmaceutical products. It does not sell products under any specific brand name, focusing instead on contract manufacturing or generic supply.
Brand Portfolio
None. The company explicitly states it does not sell products under any brand name.
New Products/Services
The company is looking at different opportunities in untapped markets for selective products it already deals in, though specific new product names are not disclosed.
Market Expansion
Expansion plans focus on the Indian market through alliances and tapping into value chains where the company can leverage its Roorkee manufacturing unit.
Strategic Alliances
The company is planning alliances with business associates in the Indian market to boost selective product lines.
External Factors
Industry Trends
The pharmaceutical industry is undergoing consolidation. Success depends on developing a dedicated team of skilled manpower and expanding manufacturing capacities to meet stringent health and safety norms.
Competitive Landscape
The industry is characterized by consolidation and a high need for skilled manpower to manage complex manufacturing and regulatory requirements.
Competitive Moat
The company's moat is its lean manufacturing model and established facility in Roorkee; however, the lack of brand ownership makes this moat vulnerable to low-cost competition and material price shocks.
Macro Economic Sensitivity
Highly sensitive to inflation in raw material prices given that materials constitute over 90% of the cost structure.
Consumer Behavior
Customer satisfaction is driven by product quality rather than brand recognition, as the company operates in the unbranded segment.
Regulatory & Governance
Industry Regulations
Operations must comply with the Companies Act, 2013, and Accounting Standard 17 for segment reporting. The company maintains an Audit Trail (Edit Log) facility in its accounting software as required by law.
Environmental Compliance
The company conducts regular environmental audits and hazard studies, submitting statutory reports to regulators periodically to comply with new health and safety norms.
Taxation Policy Impact
The company reported a Net Profit Before Tax of INR 30.58 Lakhs for FY25. Specific tax rate percentages are not detailed in the snippets.
Legal Contingencies
The company reported that no investor complaints were pending as of November 12, 2025. No specific pending court cases with values were disclosed in the provided documents.
Risk Analysis
Key Uncertainties
The primary uncertainty is the high concentration of costs in raw materials (91% of revenue), which leaves the company with a very low margin of safety (2% NPBT) against market volatility.
Geographic Concentration Risk
Manufacturing is concentrated in a single unit at Roorkee, Haridwar, making operations vulnerable to regional disruptions.
Third Party Dependencies
High dependency on business associates for market expansion and significant credit exposure to Blue Nile Capital Advisory Limited (INR 504.43 Lakhs).
Technology Obsolescence Risk
The company uses accounting software with Audit Trail features to meet regulatory standards, but specific manufacturing technology risks are not disclosed.
Credit & Counterparty Risk
Trade receivables stood at INR 554.63 Lakhs as of September 2025. There is significant counterparty risk regarding the INR 504.43 Lakhs inter-corporate loan and INR 249.43 Lakhs customer advances.
